Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations

American Journal of Pathology

Volumn 162, Issue 2, 2003, Pages 681-689

  Tierens, Anne ^a   Delabie, Jan ^a   Malecka, Agnieszka ^a   Wang, Junbai ^a   Gruszka Westwood, Alicja ^b   Catovsky, Daniel ^b   Matutes, Estella ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLICULAR LYMPHOMA; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; PHENOTYPE; PRIORITY JOURNAL; SPLENIC MARGINAL ZONE LYMPHOMA;

EID: 0037331753     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63862-X     Document Type: Article

References (52)

1. Isaacson PG, Piris MA, Catovsky D, Swerdlow S, Montserrat E, Berger F, Müller-Hermelink HK, Nathwani B, Harris N: Splenic marginal zone lymphoma. Tumours of Hematopoietic and Lymphoid Tissues. Edited by ES Jaffe, NL Harris, H Stein, JW Vardiman. Lyon, IARC Press, 2001, pp 135-137
2. Neiman RS, Sullivan AL, Jaffe R: Malignant lymphoma simulating leukemic reticuloendotheliosis. A clinicopathologic study of ten cases. Cancer 1979, 43:329-342
3. Melo JV, Hegde U, Parreira A, Thompson I, Lampert I, Catovsky D: Splenic B-cell lymphoma with circulating villous lymphocytes: differential diagnosis of B-cell leukemias with large spleens. J Clin Pathol 1987, 40:642-651
4. Catovsky D, Matutes E: Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999, 36:148-154
5. Isaacson P, Matutes E, Bruke M, Catovsky D: The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994, 84:3828-3834
6. Matutes E, Owusu-Ankomah K, Morilla R, Garcia-Marco J, Houlihan A, Que TH, Catovsky D: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640-1645
7. Troussard X, Mauvieux L, Radford-Weiss I, Rack K, Valensi F, Garand R, Vekemans M, Flandrin G, Macintyre EA: Genetic analysis of splenic lymphoma with villous lymphocytes: a groupe Francais d'hematologie cellulaire (GFHC) study. Br J Haematol 1998, 101:712-721
8. Gruszka-Westwood AM, Matutes E, Cognet LJA, Wotherspoon A, Catovsky D: The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol 1999, 104:600-604
9. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez P, Piris MA: 7q31-31 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999, 154:1583-1589
10. Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG: Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosomal 7q translocation. Oncogene 1999, 18:6271-6277
11. Hernandez JM, Garcia JL, Gutierrez NC, Mollejo M, Marinez-Climent JA, Flores T, Gonzalez MB, Piris MA, San-Miguel JF: Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol 2001, 158:1843-1850
12. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D: p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001, 97:3552-3558
13. H somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002, 99:1299-1304
14. Stevenson FK, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, Hamblin T: Insight into the origin and clonal history of B-cell tumours as revealed by analysis of immunoglobulin variable region genes. Immunol Rev 1998, 162:247-259
15. Küppers R, Klein U, Hansmann ML, Rajewsky K: Cellular origin of human B-cell lymphomas. N Engl J Med 1999, 341:1520-1529
16. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854
17. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtmand SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847
18. Zhu D, Oscier DG, Stevenson FK: Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes. Blood 1995, 85:1603-1607
19. Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG: Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests on-going mutation. Hum Pathol 1998, 29:585-593
20. Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL: Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol 1999, 30:306-312
21. Tierens A, Delabie J, Pittaluga S, Driessen A, De Wolf-Peeters C: Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets. Blood 1998, 91:2381-2386
22. Bahler DW, Pindzola JA, Swerdlow SH: Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol 2002, 161:81-88
23. Matutes E, Morillo R, Owusu-Ankomah K, Houlihan A, Catovsky D: The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994, 83:1558-1562
24. Küppers R, Zhao M, Hansmann ML, Rajewsky K: Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993, 12:4955-4967
25. Chang WC, Casali P: The CDR1 sequences of a major proportion of germline Ig VH genes are inherently susceptible to amino-acid replacement. Immunol Today 1994, 15:367-373
26. Lossos IS, Tibshirani R, Narasimhan B, Levy R: The inference of antigen selection on Ig genes. J Immunol 2000, 165:5122-5126
27. Dunn-Walters DK, Spencer J: Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. Immunology 1998, 95:339-345
28. Corbett SJ, Tomlinson IM, Sonnhammer ELL, Buck D, Winter G: Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, 'minor' D segments or D-D recombination. J Mol Biol 1997, 270:587-597
29. Dunn-Walters DK, Isaacson PG, Spencer J: Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. J Exp Med 1995, 182:618-624
30. Tierens A, Delabie J, Michiels L, Vandenberghe P, De Wolf-Peeters C: Marginal zone B cells in the lymph node and the spleen show somatic hypermutation and display clonal expansion. Blood 1999, 93:226-234
31. Amlot PL, Hayes AE: Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for postsplenectomy infections. Lancet 1985, 1:1008-1011
32. Martin F, Oliver AM, Kearney JF: Marginal zone and B1 B cells unite in the in the early response against T-independent blood-borne particulate antigens. Immunity 2001, 14:617-629
33. Zhu D, Thompsett AR, Bedu-Addo G, Stevenson FK, Bates I: VH gene sequences from a novel tropic splenic lymphoma reveal a naive B cell as the cell of origin. Br J Haematol 1999, 107:114-120
34. Bates I, Bedu-Addo G, Bevan DH, Rutherford TR: Use of immunoglobulin gene rearrangements to show clonal lymphoproliferation in hyper-reactive malarial splenomegaly. Lancet 1991, 337:505-507
35. Bates I, Bedu-Addo G, Rutherford TR, Bevan DH: Splenic lymphoma with villous lymphocytes in tropical West-Africa. Lancet 1992, 340:575-577
36. Kumar N, Zheng H: Evidence for epitope-specific thymus independent response against a repeat sequence in a protein antigen. Immunology 1998, 94:28-34
37. Bahler DW, Miklos JA, Swerdlow SH: Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997, 89:3335-3344
38. Du M, Diss TC, Xu CC, Peng H, Isaacson PG, Pan L: Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996, 10:1190-1197
39. Conconi F, Bertoni F, Pedrinis E, Motta T, Roggero E, Luminari S, Capella C, Bonato M, Cavalli F, Zucca E: Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001, 98:781-786
40. Weller S, Faili A, Garcia C, Braun MC, LeDeist FF, de Saint Basile GG, Hermine O, Fischer A, Reynaud CA, Weijl JF: CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA 2001, 98:1166-1170
41. Facchetti F, Appiani C, Salvi L, Levy J, Notarangolo LD: Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J Immunol 1995, 154:6624-6633
42. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA: Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993, 361:539-541
43. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M: The CD40 ligand, gp 39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993, 72:291-308
44. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK: CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993, 259:990-993
45. Schroeder HW, Dighiero D: The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994, 15:288-294
46. Fais F, Ghiotto F, Hashimoto S, Sellers B, Valetto A, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder Jr HW, Ferrarini M, Chiorazzi N: Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102:1515-1525
47. Hardy RR, Hayakawa K: Developmental origins specificities and immunoglobulin gene biases of murine Ly-1 B cells. Intern Rev Immunol 1992, 8:189-207
48. Kearney JF: CD5+ B-cell networks. Curr Opin Immunol 1993, 5:223-226
49. Chen X, Martin KA, Forbush KA, Perlmutter RM, Kearney JF: Evidence for selection of a population of multireactive B cells into the splenic marginal zone. Int Immunol 1997, 9:27-41
50. Pers JO, Jamin C, Predine-Hug P, Lydyard P, Yuoinou P: The role of CD5-expressing B cells in health and disease. Int J Mol Med 1999, 3:239-245
51. Gary-Gouy H, Schmitt P, Dalloul A, Daeron M, Bismuth G: The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J Biol Chem 2000, 275:548-556
52. Simarro M, Calvo J, Vila JM, Places L, Padilla O, Alberola-Ila J, Vives J, Lozano F: Signaling through CD5 involves acidic sphingomyelinase, protein kinase C-zeta, mitogen-activated protein kinase, and c-Jun NH2-terminal kinase. J Immunol 1999, 162:5149-5155